Lindsay Brigitte Ute 4

What Happened

• Lindsay Brigitte Ute, Chief Accounting Officer of Cardiff Oncology (CRDF), was granted 200,000 derivative shares (a stock award) on February 13, 2026. The award shows an acquisition price of $0 (i.e., granted as compensation rather than a purchase). This is an award/grant transaction (code A), not a sale or open-market purchase.

Key Details

• Transaction date: February 13, 2026; Form 4 filed February 18, 2026 (filed one business day late vs. the 2-business-day rule).
• Shares granted: 200,000 derivative shares; acquisition price reported as $0 (no cash paid at grant).
• Shares owned after transaction: not disclosed in the filing.
• Vesting (footnote F1): 50,000 shares vest on February 13, 2027, then 4,166 shares vest monthly for 36 months thereafter.
• Transaction type: Award/Grant (A); not a sale or purchase; no immediate cash proceeds or market sale.

Context

• This grant appears to be compensation (stock award) that vests over time. Such awards are common for executive compensation and do not indicate an immediate purchase or sale of stock. The shares are not likely transferable/marketed until they vest under the stated schedule.